1. Introduction {#sec1}
===============

Periodontal disease is a common multifactorial disease that affects nearly all ages, with some groups being more susceptible. The main risk factors are smoking, poor dental care, systemic diseases such as diabetes, certain drugs, age and stress. Besides, genetic factors are regarded as contributing factors in its pathogenesis. Based on its high prevalence, periodontal disease is regarded as a public health problem \[[@bib1]\]. The induction of inflammatory reaction to bacteria in the dental biofilm is the main pathogenic event in the periodontitis. Although certain microorganisms are linked with the progressive forms of this disorder; the existence of these microbes in persons with no sign of periodontitis implies that periodontitis is caused as the consequence of the inflammatory responses, not the sole existence of the microorganisms \[[@bib2]\]. Regulation of immune responses is a complicated process in which several coding and non-coding genes participate \[[@bib3]\]. Among non-coding RNAs whose roles in the pathogenesis of immune-related disorders have been identified are metastasis associated lung adenocarcinoma transcript 1 (*MALAT1*) \[[@bib4],[@bib5]\] and antisense non-coding RNA in the INK4 locus (*ANRIL*) \[[@bib6]\]. *MALAT1* has been shown to be over-expressed patients with systemic lupus erythematous (SLE) patients \[[@bib4]\]. Notably, *MALAT1* knock down considerably decreased the expression of IL-21 in primary monocytes of these patients. Additional studies have shown that *MALAT1* role in the pathogenesis of SLE is exerted through regulation of SIRT1 signaling \[[@bib4]\], a pathway which is probably important in the reactive oxygen species homeostasis in the process of development of periodontitis \[[@bib7]\]. Moreover, *MALAT1* has been upregulated in response to lipopolysaccharide (LPS) \[[@bib8]\]. Meanwhile, LPS has a pivotal role in the pathophysiology of periodontitis \[[@bib9]\] in a way that severe periodontitis stimulates macrophage functions through this substance \[[@bib10]\]. Expression of *MALAT1* has been up-regulated in primary human gingival fibroblasts obtained from patients with periodontitis compared with controls. This lncRNA also enhances expression of inflammatory cytokines through sponging miR‐20a and releasing toll like receptor 4 \[[@bib11]\].

*ANRIL* has a prominent role in the pathogenesis of immune-related disorders including coronary artery disease (CAD) \[[@bib12]\], type 2 diabetes \[[@bib13]\] and cancers \[[@bib14]\] as revealed by genome wide association studies. Most notably, the genomic locus for this lncRNA has been identified as a risk locus for periodontitis by various research groups \[[@bib15], [@bib16], [@bib17]\]. This lncRNA modulates immune response through interaction with the Yin Yang 1 protein \[[@bib18]\], a transcription repressor which contribute in the regulation of immune reactions \[[@bib19]\]. Certain polymorphisms within *ANRIL* have been associated with levels of C reactive protein (CRP) in CAD patients. Meanwhile, levels of this inflammation mediator have been correlated with severe periodontitis in these patients \[[@bib20]\]. Moreover, expression of this lncRNA has been induced in gingival tissues following bacterial infection \[[@bib21]\].

Although the role of lncRNAs in the pathophysiology of periodontitis has been uncovered \[[@bib22]\], data regarding expression pattern of *ANRIL* or *MALAT1* in gingival tissues or peripheral blood of patients with periodontitis is scarce. Thus, in the current study, we investigated expression of these lncRNAs in these two sets of samples obtained from patients with periodontitis and healthy subjects.

2. Material and methods {#sec2}
=======================

2.1. Enrolled individuals {#sec2.1}
-------------------------

Tissue samples were obtained during surgical procedure. Cases had the following criteria: chronic periodontitis (Stage II to IV) with at least two remaining periodontal pockets in each sextant after nonsurgical periodontal treatment, probing depth of 5 mm or greater, bleeding on probing (BOP), and at least 3 mm of attachment loss needing surgical periodontal treatment \[[@bib23]\]. Moreover, they were older than 18 years and had at least 16 teeth. Exclusion criteria were smoking, systemic diseases, history of consumption of antibiotic or anti-inflammatory drugs 3 months prior to surgical procedures, pregnancy and breastfeeding. Diagnosis of periodontitis was based on the clinical and radiographic examinations performed by a periodontist. Control samples were obtained from BOP sites of patients who underwent crown lengthening. The sites were examined by a periodontist and sites with no BOP and less than 3 mm probing depths were included. The study protocol was approved by ethical committee of Shahid Beheshti University of Medical Sciences (Ethic Code: IR.SBMU.DRC.REC.1398.086).

2.2. Expression assays {#sec2.2}
----------------------

Total RNA was extracted from both tissue and blood specimens by using Hybrid-RTM blood RNA extraction kit (GeneAll, Seoul, South Korea) according to the protocol provided by the company. The, cDNA was produced from RNA using the OneStep RT-PCR Series Kit (BioFact™, Seoul, South Korea). Relative expressions (RE) of *ANRIL* and *MALAT1* were measured in all specimens using the RealQ Plus 2x PCR Master Mix Green Without ROX™ PCR Master Mix (Ampliqon, Odense, Denmark). Reactions were conducted in StepOnePlus™ RealTime PCR equipment (Applied Biosystems, Foster city, CA, USA) in duplicate. *B2M* gene was used as normalizer. [Table 1](#tbl1){ref-type="table"} shows the sequences of primers and length of PCR products.Table 1Sequences of primers and length of PCR products.Table 1lncRNAPrimerSequenceProduct length*ANRIL*Forward\
ReverseTGCTCTATCCGCCAATCAGG\
GCGTGCAGCGGTTTAGGTTT108 bp*MALAT1*Forward\
ReverseGACGGAGGTTGAGATGAAGC\
ATTCGGGGCTCTGTAGTCCT84 bp*B2M*Forward\
ReverseAGATGAGTATGCCTGCCGTG\
GCGGCATCTTCAAACCTCCA105 bp

2.3. Statistical methods {#sec2.3}
------------------------

Transcript quantities of *ANRIL* and *MALAT1* were compared between periodontitis patients and healthy subjects using Bayesian regression model. The effects of independent variables were adjusted. Statistical analyses were performed in R 3.6.2 software, Rstan, ggplot 2 & non-parametric quantile regression packages. Bootstrap method and 100 iteration methods were used. Correlations between expressions of lncRNAs were evaluated through calculation of Spearman correlation coefficients.

3. Results {#sec3}
==========

3.1. General characteristics of periodontitis patients and controls {#sec3.1}
-------------------------------------------------------------------

The study included tissue samples from 30 patients with periodontitis (19 females, 11 males) and 30 controls (14 females, 16 males). We also gathered blood samples from 23 patients and 18 healthy controls. [Table 2](#tbl2){ref-type="table"} summarizes the demographic data of periodontitis patients and controls.Table 2General data of periodontitis patients and controls.Table 2PatientsHealthy controlsTotal Number of Tissues3030SexFemale1914Male1116Age (mean ± SD)41.28 ± 2.738.8 ± 1.9Total Number of Blood Samples2318SexFemale1511Male87Age (mean ± SD)39.65 ± 3.137.91 ± 2.8

3.2. Expression assays {#sec3.2}
----------------------

[Fig. 1](#fig1){ref-type="fig"} shows relative expression (RE) of *ANRIL* and *MALAT1* in tissue and blood samples obtained from patients and controls.Fig. 1Relative expression (RE) of *ANRIL* and *MALAT1* in tissue and blood samples obtained from patients and controls.Fig. 1

Expression of *ANRIL* was significantly lower in peripheral blood of patients compared with controls (Posterior Beta of RE = -1.734, P value = 0.035). However, when diving study participants based on their gender, no significant difference was found between patients and sex-matched controls (Posterior Beta of RE \[95% CI\] = -2.537 \[-7.43, 2.59\], P value = 0.043 for males; Posterior Beta of RE \[95% CI\] = -1.62 \[-3.44, 0.45\], P value = 0.209 for females). Expression of this lncRNA was not different between periodontitis tissues and normal tissues (Posterior Beta of RE = 0.549, P value = 0.12). This pattern was also seen among male subgroups (Posterior Beta of RE = 1.256, P value = 0.504) and among female subgroups (Posterior Beta of RE = 0.4, P value = 0.568). There was no correlation between tissue/blood levels of this lncRNA and age in either subgroups ([Table 3](#tbl3){ref-type="table"}).Table 3Relative expression of *ANRIL* in tissues and blood specimens of periodontitis patients compared with controls (RE: relative expression, SE: standard error, CrI: credible interval).Table 3TissueBloodParameters and groupsVariablePosterior Beta of RESEP-Value95% CrI for REPosterior Beta of RESEP-Value95% CrI for RETotalCase/Control0.5490.6840.12\[-0.71, 1.98\]**−1.7340.8710.035\[-3.46, -0.03\]**Gender (F/M)0.1950.6730.522\[-1.22, 1.42\]1.2820.8150.482\[-0.29, 2.92\]Age (year)0.0210.0320.635\[-0.04, 0.08\]0.0560.0730.255\[-0.08, 0.2\]MaleCase/Control1.2561.2720.504\[-1.07, 3.87\]−2.5372.5380.043\[-7.43, 2.59\]Age (year)0.0740.0540.141\[-0.03, 0.18\]0.0510.130.33\[-0.19, 0.31\]FemaleCase/Control0.40.7780.568\[-1.06, 2.01\]−1.620.9950.209\[-3.44, 0.45\]Age (year)−0.0240.0390.287\[-0.11, 0.05\]0.1190.0820.109\[-0.04, 0.28\]

Expression of *MALAT1* was not different between blood/gingival tissues of patients compared with controls (Posterior Beta of RE = 0.939, P value = 0.404 for tissues; Posterior Beta of RE = 0.055, P value = 0.605 for blood samples). Assessment of its expression levels in sex-based groups revealed no significant difference either between male patient and male controls (Posterior Beta of RE = 2.436, P value = 0.116 for tissues; Posterior Beta of RE = 0.595, P value = 0.64 for blood samples) or between female patients and female controls (Posterior Beta of RE = -0.161, P value = 0.88 for tissues; Posterior Beta of RE = 0.043, P value = 0.64 for blood samples) ([Table 4](#tbl4){ref-type="table"}).Table 4Relative expression of *MALAT1* in tissues and blood specimens of periodontitis patients compared with controls (RE: relative expression, SE: standard error, CrI: credible interval).Table 4TissueBloodParameters and groupsVariablePosterior Beta of RESEP-Value95% CrI for REPosterior Beta of RESEP-Value95% CrI for RETotalCase/Control0.9391.2640.404\[-1.6, 3.4\]0.0550.4940.605\[-0.89, 1.04\]Gender (F/M)1.6511.0670.038\[-0.46, 3.64\]−0.4630.3760.091\[-1.27, 0.24\]Age (year)−0.0060.0610.608\[-0.12, 0.11\]−0.0170.0280.676\[-0.07, 0.04\]MaleCase/Control2.4361.8870.116\[-1.33, 5.98\]0.5951.20.64\[-1.67, 2.98\]Age (year)−0.0180.0790.734\[-0.17, 0.15\]−0.0460.0550.782\[-0.15, 0.06\]FemaleCase/Control−0.1611.5890.88\[-3.2, 2.96\]0.0430.6540.64\[-1.26, 1.37\]Age (year)−0.0340.0780.798\[-0.18, 0.12\]−0.0010.0490.341\[-0.1, 0.1\]

3.3. Correlation between expression levels of *ANRIL* and *MALAT1* lncRNAs and age of enrolled individuals {#sec3.3}
----------------------------------------------------------------------------------------------------------

Tissue or blood expressions of *ANRIL* or *MALAT1* were not correlated with age of either patients or controls ([Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}). There were significant correlations between expression levels of *ANRIL* and *MALAT1* in gingival tissues both in cases (r = 0.62, P \< 0.0001) and in controls (r = 0.37, P \< 0.0001). However, blood levels of these lncRNAs were not correlated with each other either in cases (r = -0.24, P = 0.208) or in controls (P = 0.588). Most notably, there was no significant correlation between expression levels of these lncRNAs in gingival tissues and in the blood of study participants (P = 0.556 for *ANRIL* and P = 0.388 for *MALAT1*) ([Fig. 2](#fig2){ref-type="fig"}, [Fig. 3](#fig3){ref-type="fig"}).Fig. 2Correlation between expression levels of lncRNAs and age of periodontitis patients.Fig. 2Fig. 3Correlation between expression levels of lncRNAs and age of controls.Fig. 3

4. Discussion {#sec4}
=============

In the present study, we investigated expression of two lncRNAs in peripheral blood and affected gingival tissues of patients with periodontitis and healthy subjects. Expression of *ANRIL* was significantly lower in peripheral blood of patients compared with controls. However, expression of this lncRNA was not different between periodontitis tissues and normal tissues. This lncRNA has been recognized as a shared locus for both periodontitis and CAD \[[@bib17]\]. Consistent with the mentioned results, a recent study demonstrated down-regulation of *ANRIL* in peripheral blood of CAD patients compared with healthy subjects \[[@bib24]\]. Another study showed down-regulation of the main endothelial cell-associated transcript of *ANRIL* in CAD coronary arteries compared with non-CAD arteries, thus indicating the protective role for *ANRIL* against CAD \[[@bib25]\]. Our present results also imply a protective role for this lncRNA against periodontitis, a disorder which has been linked with CAD in both genetic risks \[[@bib17]\] and mechanisms \[[@bib9]\]. Furthermore, the rs1333048 polymorphism within *ANRIL* has been associated with higher plasma levels of C reactive protein (CRP) in patients with periodontitis \[[@bib26]\]. Notably, CRP is regarded a marker for CAD as well \[[@bib27]\].

Expression of *MALAT1* was not different between tissue or blood samples obtained from cases and controls. This lncRNA has been demonstrated to modulate immune responses \[[@bib3]\]. Its silencing has enhanced expression of TNF-α and IL-6 cytokines \[[@bib8]\]. In addition, *MALAT1* has an inhibitory effect on NF-κB signaling, pathway that regulates several aspects of inflammatory responses \[[@bib8]\]. This lncRNA also modulates macrophage activation to induce differentiation of M2 macrophages \[[@bib28]\]. Notably, *in silico* analysis of miRNA and mRNA expression profiles has shown the role of *MALAT1* in construction of the lncRNA-associated competing endogenous RNA network of periodontitis \[[@bib22]\]. Our result was not consistent with the supposed role of this lncRNA in the pathogenesis of immune-related disorders. This might indicate different roles of this lncRNA in the pathogenesis of different immune-related disorders.

Besides, tissue or blood expressions of *ANRIL* or *MALAT1* were not correlated with age of either patients or controls. Thus, if future studies reveal the biomarker role for *ANRIL*, as expression of this lncRNA is not influenced by the age, this biomarker can be used for follow-up of patients during long periods of time.

There were significant correlations between expression levels of *ANRIL* and *MALAT1* in gingival tissues both in cases and in controls. However, blood levels of these lncRNAs were not correlated with each other either in cases or in controls. These observations may indicate the presence of tissue-specific regulatory mechanisms or interaction networks between these lncRNAs which should be explored in future studies. Consistent with this hypothesis, there was no significant correlation between expression levels of these lncRNAs in gingival tissues and in the blood of study participants.

The current study indicates dysregulation of *ANRIL* in the peripheral blood of patients with periodontitis in spite of its normal levels in gingival tissues which might reflect disturbance in systemic immune responses in these patients. Most notably, this finding is in line with the role of *ANRIL* in the pathogenesis of CAD, a disease which is genetically and mechanistically related with periodontitis.
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